These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37439077)

  • 1. Preparing for long-acting PrEP delivery: building on lessons from oral PrEP.
    Celum C; Grinsztejn B; Ngure K
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26103. PubMed ID: 37439077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery.
    Celum CL; Delany-Moretlwe S; Baeten JM; van der Straten A; Hosek S; Bukusi EA; McConnell M; Barnabas RV; Bekker LG
    J Int AIDS Soc; 2019 Jul; 22 Suppl 4(Suppl Suppl 4):e25298. PubMed ID: 31328444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Need for informed providers: exploring LA-PrEP access in focus groups with PrEP-indicated communities in Baltimore, Maryland.
    Kaptchuk RP; Thomas AM; Dhir AM; Solomon SS; Clipman SJ
    BMC Public Health; 2024 May; 24(1):1258. PubMed ID: 38720248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learnt from daily oral PrEP delivery to inform national planning for PrEP ring introduction for women in low-income and middle-income countries: a qualitative inquiry of international stakeholders.
    Heck CJ; Dam A; Yohannes K; Deacon J; Kripke K; Meyers K; Poku O; Obermeyer C; Wiant S; Quigee D; Larson M; Malati C; Sobieszczyk ME; Torres-Rueda S; Castor D
    BMJ Glob Health; 2024 May; 9(5):. PubMed ID: 38770814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.
    Henderson M; Schmidt HA; Chitembo L; Peralta H; Alaama AS; Johnson C; Baggaley R; Schaefer R
    AIDS Behav; 2023 Nov; 27(11):3755-3766. PubMed ID: 37351685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.
    Grimsrud A; Wilkinson L; Delany-Moretlwe S; Ehrenkranz P; Green K; Murenga M; Ngure K; Otwoma NJ; Phanuphak N; Vandevelde W; Vitoria M; Bygrave H
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26095. PubMed ID: 37439076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations.
    Mgodi NM; Murewanhema G; Moyo E; Samba C; Musuka G; Dzinamarira T; Brown JM
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26115. PubMed ID: 37439069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stand-alone model for delivery of oral HIV pre-exposure prophylaxis in Kenya: a single-arm, prospective pilot evaluation.
    Ortblad KF; Mogere P; Omollo V; Kuo AP; Asewe M; Gakuo S; Roche S; Mugambi M; Mugambi ML; Stergachis A; Odoyo J; Bukusi EA; Ngure K; Baeten JM
    J Int AIDS Soc; 2023 Jun; 26(6):e26131. PubMed ID: 37306128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promises and potential pitfalls of long-acting injectable pre-exposure prophylaxis.
    Pike C; Rousseau E; Bekker LG
    South Afr J HIV Med; 2023; 24(1):1497. PubMed ID: 38089889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian Contraception Consensus (Part 2 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N
    J Obstet Gynaecol Can; 2015 Nov; 37(11):1033-9. PubMed ID: 26629725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian Contraception Consensus (Part 1 of 4).
    Black A; Guilbert E; ; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman WV; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; ; Ferguson C; Fortin C; Kielly M; Mansouri S; Todd N;
    J Obstet Gynaecol Can; 2015 Oct; 37(10):936-42. PubMed ID: 26606712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.
    Mack N; Odhiambo J; Wong CM; Agot K
    BMC Health Serv Res; 2014 May; 14():231. PubMed ID: 24886646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya.
    Wara NJ; Mvududu R; Marwa MM; Gómez L; Mashele N; Orrell C; Moucheraud C; Kinuthia J; John-Stewart G; Myer L; Hoffman R; Pintye J; Davey DLJ
    J Int AIDS Soc; 2023 May; 26(5):e26088. PubMed ID: 37221983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam.
    Doan AH; Vu CMH; Nguyen TT; Green KE; Phan HTT; Janamnuaysook R; Vu BN; Le TM; Do KQ; Tran TT; Ngo TM; Basu L; Tran LK; Humeau Z
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25996. PubMed ID: 36225133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?
    Liegeon G; Ghosn J
    HIV Med; 2023 Jun; 24(6):653-663. PubMed ID: 36468218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
    Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.